Court of Appeal, First District, Division 2, California. James CLAYWORTH, et al., Plaintiffs and Appellants, v. PFIZER, INC., et al., Defendants and Respondents.
Aug 3, 2018 ... Al Haj et al v. Pfizer Inc, No. 1:2017cv06730 - Document 83 (N.D. Ill. 2018) case opinion from the Northern District of Illinois US Federal District ...
Apr 13, 2018 ... Al Haj et al v. Pfizer Inc, No. 1:2017cv06730 - Document 60 (N.D. Ill. 2018) case opinion from the Northern District of Illinois US Federal District ...
Jul 29, 2010 ... For all markers, the pan-cytokeratin signal was used to create an epithelial “mask ” to .... histology was more frequent in the biomarker cohort than in the overall study population (41% vs. 18%) Six ..... Disclosures: This research was supported by Pfizer Inc. ... Gustavson MD, Bourke-Martin B, Reilly DM, et al.
Complete docket sheet and filings in Colgate et al v. JUUL Labs, Inc. et al, in the Northern District of California.
Oct 8, 2018 ... member of his immediate family has equity in Pfizer, Inc. RSB holds equity in, and ..... Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. ... Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, et al.
Of these, 5.8% switched, 51.3% permanently discontinued all anticholinergic agents, and .... Detrol, Detrol LA and Toviaz (Pfizer Inc., New York, New York). ‡ .... switches are almost one third the rate observed by D'Souza et al (5.8% vs 13 %). ... Ms. Migliaccio-Walle led the manuscript preparation, provided oversight and ...
Mar 5, 2015 ... Migliaccio et al.; licensee BioMed Central. 2015 ... In two trials comparing anastrozole versus tamoxifen, median TTP for anastrozole was 11.1 ...
disease throughout the world (Choo et al., 1989;. Houghton ... nience of a less frequent administration (once a week vs three times ..... the NS5B polymerase and is incorporated as monophos- phate in .... that HCV can become resistant to these NIs (Migliaccio et al. ..... Agouron/Pfizer (Chan et al., 2004a; Chan et al., 2004b;.